Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy
Open Access
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (5) , 802-817
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 30 references indexed in Scilit:
- Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistanceCurrent Opinion in Pulmonary Medicine, 2014
- Hospital-acquired pneumonia and ventilator-associated pneumoniaCurrent Opinion in Pulmonary Medicine, 2013
- The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patientsVaccine, 2012
- Economic Impact of Ventilator-Associated Pneumonia in a Large Matched CohortInfection Control & Hospital Epidemiology, 2012
- Direct Cost Analysis of Intensive Care Unit Stay in Four European Countries: Applying a Standardized Costing MethodologyValue in Health, 2012
- Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapyEuropean Journal of Medical Research, 2011
- Microbiology of Ventilator–Associated Pneumonia Compared With That of Hospital-Acquired PneumoniaInfection Control & Hospital Epidemiology, 2007
- Impact of diversity of antibiotic use on the development of antimicrobial resistanceJournal of Antimicrobial Chemotherapy, 2006
- Ventilator associated pneumoniaPostgraduate Medical Journal, 2006
- The Use of 2 Health-Related Quality-of-Life Measures in a Sample of Persons Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2001